Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer

This study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the immune cell environment within colorectal cancer metastases. The drug will be administered to patients before surgical treatment.

开始日期2016-03-14

申办/合作机构

Providence Health & Services

[+1]

NCT02274155 / Completed临床1期IIT

Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma

The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma.

开始日期2014-11-12

申办/合作机构

Providence Health & Services

[+1]

NCT02205333 / Terminated临床1/2期

A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas

The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736 (durvalumab), or rituximab in participants with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL). Tremelimumab and MEDI4736 (durvalumab) will be tested with MEDI6469 in a set of participants with advanced solid tumors while rituximab will be tested with MEDI6469 in participants with DLBCL. MEDI6469 will be tested as monotherapy in participants with advanced solid tumors.

开始日期2014-08-13

申办/合作机构

MedImmune LLC

100 项与 MEDI-6469 相关的临床结果

登录后查看更多信息

100 项与 MEDI-6469 相关的转化医学

登录后查看更多信息

100 项与 MEDI-6469 相关的专利（医药）

登录后查看更多信息

项与 MEDI-6469 相关的文献（医药）

2024-02-01·Journal of Allergy and Clinical Immunology: Global

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis

Article

作者: Martinet, Camille ; Doucey, Marie-Agnès ; Gudi, Girish ; Turrini, Riccardo ; Machkova, Martina ; Pauser, Sylvia ; Pulka, Grazyna ; Macoin, Julie ; Anstett, Victor ; Ca, Vinu ; Jabert, Wafaa ; Mozaffarian, Neelufar ; Rewerska, Barbara ; Alpizar, Sady ; Blein, Stanislas ; Sher, Lawrence D ; Gn, Sunitha ; Salhi, Yacine ; Konto, Cyril

BackgroundTelazorlimab is a humanized anti-OX40 monoclonal antibody being studied for treatment of T-cell-mediated diseases.ObjectiveThis randomized, placebo-controlled, phase 2b dose-range finding study investigated efficacy, safety, pharmacokinetics, and immunogenicity of telazorlimab in subjects with atopic dermatitis.MethodsIn this 2-part study (NCT03568162), adults (≥18 years) with moderate-to-severe disease were randomized to various regimens of subcutaneous telazorlimab or placebo for 16 weeks' blinded treatment, followed by 38 weeks' open-label treatment and 12 weeks' drug-free follow-up. Telazorlimab treatment groups (following a loading dose) in part 1 were 300 mg every 2 weeks; 300 mg every 4 weeks; or 75 mg every 4 weeks. Part 2 evaluated telazorlimab 600 mg every 2 weeks. The primary end point was percentage change from baseline in Eczema Area and Severity Index (EASI) at week 16. Safety assessments included incidence of treatment-emergent adverse events.ResultsThe study randomized 313 subjects in part 1 and 149 in part 2. At 16 weeks, the least squares mean percentage change from baseline in EASI was significantly greater in subjects receiving telazorlimab 300 mg every 2 weeks (part 1) and 600 mg every 2 weeks (part 2) versus placebo (-54.4% vs -34.2% for part 1 and -59.0% vs -41.8% for part 2, P = .008 for both). Telazorlimab was well tolerated, with similar distribution of adverse events between telazorlimab- and placebo-treated subjects in both part 1 and part 2.ConclusionTelazorlimab, administered subcutaneously at 300 mg every 2 weeks or 600 mg every 2 weeks following a loading dose, was well tolerated and induced significant and progressive clinical improvement in adults with moderate-to-severe atopic dermatitis.

2023-11-01·International Immunopharmacology

Corrigendum to “Photothermic therapy with cuttlefish ink-based nanoparticles in combination with anti-OX40 mAb achieve remission of triple-negative breast cancer” [Int. Immunopharmacol. 115 (2023) 109622]

作者: Mohammadi, Mohsen ; Nabipour, Iraj ; Kabiri-Samani, Saber ; Nazaraghay, Roghayeh ; Shabankareh, Azar Najafi Tireh ; Kabiri, Hamidreza ; Ghavimi, Reza ; Hajian, Sobhan ; Momenzadeh, Niloofar ; Shabankare, Atefe ; Hesami-Zadeh, Khashayar

2023-10-25·British Journal of Dermatology

Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

Article

作者: Reich, Adam ; Quaratino, Sonia ; O’Malley, John T ; Brennan, Nuala ; Gilbert, Sally ; Cork, Michael J ; Weidinger, Stephan ; Bieber, Thomas ; Wilson, Rosamund ; Stebegg, Marisa ; Porter-Brown, Ben

AbstractBackgroundAtopic dermatitis (AD) is an inflammatory skin disease with significant unmet need. Blockade of the OX40–OX40 ligand (OX40L) costimulation pathway by targeting OX40L on antigen-presenting cells (APCs) with a fully human noncytotoxic, nondepleting anti-OX40L monoclonal antibody (amlitelimab; SAR445229; KY1005) is a novel way to modulate persistent inflammation.ObjectivesTo assess the safety and efficacy of amlitelimab over 16 weeks in adults with AD in a phase IIa double-blind placebo-controlled study.MethodsThe study was conducted at 19 hospitals in Germany, Poland, Spain and the UK. Eligible patients with moderate-to-severe AD were randomized (1 : 1 : 1) to low-dose intravenous (IV) amlitelimab (200 mg), high-dose IV amlitelimab (500 mg) or placebo, followed by three maintenance doses (50% of loading dose) at 4, 8 and 12 weeks, with safety follow-up to week 36. The co-primary endpoints were the incidence of treatment-emergent adverse events (all patients who received ≥ 1 dose of the study drug) and mean percentage change in Eczema Area and Severity Index (EASI) to week 16 (full analysis set).ResultsBetween 13 December 2018 and 12 May 2020, 89 patients were randomly assigned to low- (n = 29) or high-dose amlitelimab (n = 30) or placebo (n = 29), of whom 88 proceeded to treatment [37 women (42%), 51 (58%) men; mean (SD) age 33.6 (11.9) years]. Amlitelimab was generally well tolerated with an unremarkable safety profile; no hypersensitivity events were reported. For the primary endpoint, the least square mean percentage change in EASI from baseline to week 16 was –80.12% [95% confidence interval (CI) –95.55 to –64.68; P = 0.009 vs. placebo] and –69.97% (95% CI –85.04 to –54.60; P = 0.07 vs. placebo) for the low- (n = 27) and high-dose (n = 27) amlitelimab groups, respectively, vs. –49.37% (95% CI –66.02 to –32.72) for placebo (n = 24). Numerically greater reductions in EASI were observed for amlitelimab vs. placebo from weeks 2 to 16.ConclusionsNovel targeting of OX40L-expressing APCs with amlitelimab was well tolerated and resulted in clinically meaningful improvements in AD.

项与 MEDI-6469 相关的新闻（医药）

2024-09-25

·PRNewswire

Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis

Rocatinlimab Met Co-Primary Endpoints of vIGA-ADTM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints HORIZON is the First of Eight Phase 3 Trials in the ROCKET Program TOKYO, Sept. 25, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor. HORIZON met its co-primary endpoints: achievement of a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) score of 0 (clear) or 1 (almost clear) with a ≥ 2-point reduction from baseline [19.3% rocatinlimab vs. 6.6% placebo (12.8% difference, p<0.001)] and achievement of ≥ 75% reduction from baseline in Eczema Area and Severity Index score (EASI-75) [32.8% rocatinlimab vs. 13.7% placebo (19.1% difference, p<0.001)], both at week 24. The trial also met the revised Investigator Global Assessment (rIGA 0/1) *[1], a more stringent measure of efficacy than vIGA 0/1 based on a narrower definition of 1 (almost clear), at week 24 [16.4% rocatinlimab vs. 4.9% placebo (11.5% difference, p<0.001)]. HORIZON is a Phase 3, 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety and tolerability of rocatinlimab monotherapy in adults with moderate to severe atopic dermatitis (eczema). HORIZON is one of eight studies in the global ROCKET Phase 3 clinical trial program. The study also reached statistically significant differences from placebo for all key secondary endpoints, which include measurements of skin clearance (vIGA 0/1 and EASI-75 at week 16 and EASI-90 at week 24), the Pruritus Numeric Rating Scale, Atopic Dermatitis Skin Pain Scale, Dermatology Quality of Life Index, and severity scores of hand atopic dermatitis and facial atopic dermatitis. Overall safety findings in ROCKET HORIZON were comparable to those seen in the Phase 2b study. 1 "We are very pleased to have achieved statistically significant efficacy results over placebo which are consistent for co-primary endpoints and all key secondary endpoints. We look forward to further demonstrating that rocatinlimab, a potential T-cell rebalancing therapy, may help patients with moderate to severe atopic dermatitis as a new therapeutic option. We anticipate getting additional data from the ROCKET program and fully understanding the value rocatinlimab can deliver to patients." said Takeyoshi Yamashita, Ph.D., senior managing executive officer and chief medical officer at Kyowa Kirin. Detailed results of HORIZON will be provided at a future medical congress. Amgen and Kyowa Kirin plan to review HORIZON and forthcoming results from the other seven studies in the ROCKET program as part of ongoing discussions with global regulatory authorities. The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies. ROCKET HORIZON and the ROCKET Phase 3 Program ROCKET HORIZON is a Phase 3, randomized, placebo-controlled, double-blind trial assessing the efficacy, safety and tolerability of rocatinlimab monotherapy in adults with moderate to severe atopic dermatitis. The trial includes 726 adult patients who were randomized to receive rocatinlimab or placebo administered through a subcutaneous injection every four weeks for 24 weeks with a loading dose at week two.2 Key endpoints were assessed at week 16 and week 24. Co-primary endpoints for the trial are achievement of a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) score of 0 (clear) or 1 (almost clear) with a ≥ 2-point reduction from baseline at week 24 and achievement of ≥ 75% reduction from baseline in Eczema Area and Severity Index score (EASI-75) at week 24. (In the US, revised Investigator Global Assessment (rIGA) replaces vIGA as co-primary endpoint). Key secondary endpoints assess the impact of rocatinlimab on itch, sleep, and quality of life as well as safety and tolerability. ROCKET is a comprehensive, global Phase 3 clinical trial program comprised of eight studies intended to establish the safety and efficacy profile of rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) as well as multiple dosing regimens. About Moderate to Severe Atopic Dermatitis Atopic dermatitis, the most common form of eczema, is a chronic inflammatory disease that causes excessively dry, itchy skin that can be painful.3,4 People with moderate to severe atopic dermatitis experience chronic symptoms, intensified by unpredictable flare-ups that can be painful and disruptive to everyday life.4 Almost half of these patients report severe itching, leading to repeated scratching which can cause the skin to thicken and become vulnerable to infection.5,6,7 Atopic dermatitis (all severities) affects 15-20% of children and up to 10% of adults.8 T-cell imbalance is a root cause of atopic dermatitis, contributing to clinical manifestations including the disease's recurring, unpredictable symptoms.9 About Rocatinlimab Rocatinlimab is an anti-OX40 human monoclonal antibody being investigated for the treatment of moderate to severe atopic dermatitis. Rocatinlimab has the potential to be the first and only T-cell rebalancing therapy that inhibits and reduces pathogenic T cells by targeting the OX40 receptor. OX40 is a co-stimulatory receptor responsible for driving systemic and local inflammatory responses in atopic dermatitis and other conditions.9 It has been reported that effector T cells expressing OX40 are present in the lesions of patients with atopic dermatitis and are critical in the disease pathophysiology.10,11 Rocatinlimab is also being studied for moderate to severe uncontrolled asthma, prurigo nodularis and potentially other conditions where T-cell imbalance is a root cause of inflammation. The initial antibody was discovered in collaboration between Kyowa Kirin and La Jolla Institute for Immunology. Rocatinlimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by the U.S. FDA or any other regulatory authority. Amgen and Kyowa Kirin Collaboration On June 1, 2021, Kyowa Kirin and Amgen entered into an agreement to jointly develop and commercialize rocatinlimab. Under the terms of the agreement, Amgen will lead the development, manufacturing, and commercialization for KHK4083/AMG 451 for all markets globally, except Japan, where Kyowa Kirin will retain all rights. If approved, the companies will co-promote the asset in the United States and Kyowa Kirin has opt-in rights to co-promote in certain other markets including Europe and Asia. About Kyowa Kirin Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at: . References Guttman-Yassky, E., Simpson, E. L., Reich, K., Kabashima, K., Igawa, K., Suzuki, T., Mano, H., Matsui, T., Esfandiari, E., Furue, M. (2023). An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. The Lancet, 401(10372), 204–214. doi: 10.1016/S0140-6736(22)02037-2. PMID: 36509097 Amgen. A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET HORIZON). ClinicalTrials.gov identifier: NCT05651711. Updated June 4, 2024. Accessed June 27, 2024. . Wang X, et al. Medicine (Baltimore). 2017;96:e6317 Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351. "Eczema Stats." National Eczema Association, 5 Sept. 2023, nationaleczema.org/research/eczema-facts/. "Can Anything Relieve Severe Atopic Dermatitis?" American Academy of Dermatology, . Accessed 23 Sept. 2024. "What Is Moderate to Severe Eczema?" Allergy & Asthma Network, 16 May 2024, allergyasthmanetwork.org/what-is-eczema/moderate-to-severe-eczema/. Accessed 23 Sept. 2024. Ständer, M.D. Atopic Dermatitis. The New England Journal of Medicine. 2021. Agrawal R, Wisniewski JA, Woodfolk JA. The role of regulatory T cells in atopic dermatitis. Curr Probl Dermatol. 2011;41:112-124. doi: 10.1159/000323305. Epub 2011 May 12. PMID: 21576952; PMCID: PMC4547455. Croft M, Esfandiari E, Chong C, Hsu H, Kabashima K, Kricorian G, Warren RB, Wollenberg A, Guttman-Yassky E. OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. Am J Clin Dermatol. 2024 May;25(3):447-461. doi: 10.1007/s40257-023-00838-9. Epub 2024 Jan 18. Erratum in: Am J Clin Dermatol. 2024 May;25(3):463. doi: 10.1007/s40257-024-00850-7. PMID: 38236520; PMCID: PMC11070399. Furue M, Furue M. OX40L-OX40 Signaling in Atopic Dermatitis. J Clin Med. 2021 Jun 11;10(12):2578. doi: 10.3390/jcm10122578. PMID: 34208041; PMCID: PMC8230615. SOURCE Kyowa Kirin WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果临床3期临床2期引进/卖出

2024-09-24

·Endpoints

Amgen reports dual Phase 3 wins in atopic dermatitis and myasthenia gravis

Amgen released data from two pivotal trials on Tuesday that showed its experimental drug rocatinlimab succeeded in a Phase 3 test in atopic dermatitis, while its approved drug Uplizna also yielded positive results in myasthenia gravis. The data are a boost to Amgen’s immunology hopes, and the success with rocatinlimab — an anti-OX40 monoclonal antibody — will solidify its advantage over Sanofi’s asset amlitelimab, which goes after a related target. The rocatinlimab results are the first of eight different Phase 3 trials Amgen is running for the drug. In Tuesday’s trial, called ROCKET-Horizon, rocatinlimab met its primary endpoint and all secondary endpoints by a statistically significant margin, Amgen said. The drug induced at least a 75% reduction in the Eczema Area and Severity Index (EASI-75) in 32.8% of patients, compared with 13.7% on placebo after 24 weeks. Amgen said that the study’s other co-primary endpoints, also measuring skin clearance, were successful as well. Sanofi has positioned amlitelimab, which binds to OX40-Ligand, as one of its key growth drivers in its pivot to immunology. But its first Phase 3 readout won’t take place until the end of 2026. In the meantime, Amgen has at least four other Phase 3 trials for rocatinlimab expected to report data before next July, including studies looking at different doses, the drug’s use as a combination or maintenance therapy, and a trial in adolescents. Amgen will likely have a significant market advantage by filing for rocatinlimab approval much earlier, although on a conference call Tuesday, CSO Jay Bradner didn’t say when it might file with the FDA. Amgen licensed rocatinlimab from Kyowa Kirin in 2021, a few months after it reported Phase 2 results, paying $400 million upfront and promising another $850 million in milestones. Sanofi acquired amlitelimab in its $1.1 billion buyout of Kymab in 2021. Sanofi is still hoping for big things from amlitelimab. Earlier this year, an early look at Phase 2b data prompted the company to amend its Phase 3 trial protocol to allow for increased time off-drug. Amgen also said Tuesday that its rare disease drug Uplizna hit its primary endpoint in a Phase 3 trial for the autoimmune disease myasthenia gravis. In a measurement scale called the Myasthenia Gravis Activities of Daily Living, or MG-ADL, two doses of Uplizna produced an improvement of -4.2 points after 26 weeks, compared with -1.9 points on placebo (p<0.0001). Four of the study’s five secondary endpoints were also statistically significant, Bradner said. The win comes a few months after Uplizna recorded a successful Phase 3 study in IgG4-related disease back in June. Uplizna was first approved in 2020 for an autoimmune disease that affects the eyes called neuromyelitis optica spectrum disorder, or NMOSD.

临床结果临床3期上市批准并购临床2期

2024-08-27

·FierceBiotech

Navigator charts course for newly acquired autoimmune pipeline with $100M series A

Navigator is planning to launch additional clinical studies with NAV-240 in the coming months. Navigator Medicines has equipped itself with $100 million in series A funds as the young biotech charts a course for its newly acquired autoimmune drugs.The company, which was founded earlier this year as a subsidiary of Sera Medicines, has bought itself a pipeline of OX40L-targeted mono- and bispecific antibodies from Korea’s IMBiologics. According to reporting shared on IMBiologics’ website, Navigator secured the licenses for the drugs outside of Asia—but including Japan—for $20 million upfront and with $924.7 million in potential milestone payments.Headlining the group is IMB101, now rebranded as NAV-240, a bispecific antibody against OX40L and TNFα in a phase 1 study in healthy subjects. OX40L and TNFα have already been established as critical in the pathogenesis of several inflammatory diseases, pointed out Navigator, which added that targeting both signaling pathways “may improve upon the efficacy of either monotherapy alone as a potential treatment option for complex, heterogeneous diseases with unmet medical needs.”IMBiologics previously touted NAV-240 as offering a fresh way to address unmet needs for a range of autoimmune diseases, including patients with rheumatoid arthritis who are non-responsive or resistant to anti-TNF agents. Navigator will be able to push ahead with these assets courtesy of $100 million from a series A funding round co-led by well-known VC names RA Capital Management and Forbion. As part of the financing, Wouter Joustra, a general partner at Forbion, and Andrew Levin, M.D., Ph.D., a partner and managing director at RA Capital Management, are joining Navigator’s board.“NAV-240 has the potential to make an impact on patients living with autoimmune diseases, and our series A funding will be pivotal in accelerating its development alongside other exciting programs within our pipeline,” said Navigator’s chief medical officer Dana McClintock, whose appointment was also announced in the same release.“We look forward to initiating additional clinical studies with NAV-240 in the coming months and delivering on our commitment to innovation that enhances patient care,” McClintock added.Last year, Sanofi pointed to positive phase 2 results for an anti-OX40-ligand monoclonal antibody called amlitelimab that it acquired as part of its Kymab buyout as proof that targeting OX40-ligand offers a therapeutic option for inflammatory diseases.

临床1期临床2期引进/卖出临床结果并购

100 项与 MEDI-6469 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15306

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床2期	美国	MedImmune LLC	2014-08-13
淋巴瘤	临床2期	美国	MedImmune LLC	2014-08-13
乳腺癌	临床2期	-	Providence Cancer Center	-
乳腺癌	临床2期	-	MedImmune LLC	-
弥漫性大B细胞淋巴瘤	临床2期	-	MedImmune LLC	-
弥漫性大B细胞淋巴瘤	临床2期	-	Providence Cancer Center	-
前列腺癌	临床2期	美国	Providence Cancer Center	-
前列腺癌	临床2期	-	MedImmune LLC	-
黑色素瘤	临床1期	-	MedImmune LLC	-
黑色素瘤	临床1期	-	Providence Cancer Center	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02274155 (Pubmed \| Nat Commun) 人工标引	临床1期	头颈部鳞状细胞癌新辅助	17	MEDI6469	(襯淵衊遞獵築網簾餘糧) = at anti-OX40 prior to surgery is safe and can increase activation and proliferation of CD4+ and CD8+ T cells in blood and tumor. 壓鹹範鹽衊構膚糧選衊 (夢壓遞鏇衊鬱製夢築齋 ) 更多	积极	2021-02-16
NCT02205333 (MEDI6469, CTgov)	临床1/2期	晚期恶性实体瘤 \| B细胞淋巴瘤	48	MEDI6469 Monotherapy (MEDI6469 6 mg/kg)	蓋襯壓積糧範膚範遞築(構構網齋製窪蓋餘蓋鬱) = 鹽網願觸襯範壓淵廠積願築繭積壓蓋築築獵壓 (觸淵艱蓋鏇鹹餘繭鹽觸, 艱廠夢願網鏇鹽膚鏇築 ~ 構衊壓築顧淵憲獵夢糧) 更多	-	2017-05-08
NCT02205333 (MEDI6469, CTgov)	临床1/2期	晚期恶性实体瘤 \| B细胞淋巴瘤	48	MEDI6469 Monotherapy (MEDI6469 10 mg/kg)	蓋襯壓積糧範膚範遞築(構構網齋製窪蓋餘蓋鬱) = 獵顧選積鑰觸蓋積觸範願築繭積壓蓋築築獵壓 (觸淵艱蓋鏇鹹餘繭鹽觸, 積襯糧鏇蓋網窪衊廠蓋 ~ 淵繭遞鬱艱廠製觸淵淵) 更多	-	2017-05-08